logo

For the Inventor, By the Inventor

Basel, Switzerland

Mathias Frederiksen

USPTO Granted Patents = 11 

 

Average Co-Inventor Count = 4.8

ph-index = 6

Forward Citations = 65(Granted Patents)


Company Filing History:

goldMedal11 out of 3,923 
 
Novartis Ag
 patents

Years Active: 2010-2017

Loading Chart...
Loading Chart...
11 patents (USPTO):Explore Patents
1. 9657010 - Substituted quinuclidines as alpha 7-nicotinic acetylcholine receptor activity modulators (2017-05-23),
2. 9475811 - 1-aza-bicyclo[3.3.1]nonanes (2016-10-25),
3. 9206181 - 1-aza-bicyclo[3.3.1] non-4-yl)-[5-(1H-indol-5-yl)-heteroaryl]-amines as cholinergic ligands of the n-AChR for the treatment of psychotic and neurodegenerative disorders (2015-12-08),
4. 8933090 - 1-aza-bicyclo[3.3.1]nonanes (2015-01-13),
5. 8759346 - Organic compounds (2014-06-24),
6. 8637517 - Organic compounds (2014-01-28),
7. 8609662 - 3-(heteroaryl-oxy)-2-alkyl-1-aza-bicycloalkyl derivatives as alpha. 7-nachr ligands for the treatment of CNS diseases (2013-12-17),
8. 8173667 - 1-aza-bicycloalkyl derivatives (2012-05-08),
9. 8048885 - Organic compounds (2011-11-01),
10. 7713977 - (1-aza-bicyclo[3.3.1]non-4-yl)-[5-(1H-indol-5-yl)-heteroaryl]-amines as cholinergic ligands of the n-achr for the treatment of psychotic and neurodegenerative disorders (2010-05-11),
11. 7713976 - [(1H-indol-5-yl)-heteroaryloxy]-1-aza-bicylco[3.3.1]nonanes as cholinergic ligands of the n-AChR for the treatment of psychotic and neurodegenerative disorders (2010-05-11),

Title: The Innovative Contributions of Mathias Frederiksen in Pharmaceutical Chemistry

Introduction

Mathias Frederiksen, a prominent inventor based in Basel, Switzerland, has made significant strides in the field of pharmaceutical chemistry. With an impressive portfolio of 11 patents, Frederiksen's work showcases his dedication to advancing medical science and improving therapeutic strategies for various disorders.

Latest Patents

Frederiksen's recent innovations include patents related to substituted quinuclidines and 1-aza-bicyclo[3.3.1]nonanes. The first patent focuses on 1-aza-bicycloalkyl derivatives that serve as modulators of the alpha 7-nicotinic acetylcholine receptor, demonstrating their potential use in preventing and treating psychotic and neurodegenerative disorders. The compounds described within this patent are known to act as ligands for nicotinic acetylcholine receptors (NACHR). Meanwhile, the second patent addresses pharmaceutical compositions comprising 1-aza-bicycloalkyl derivatives, possessing similar structural complexity and therapeutic applications.

Career Highlights

Frederiksen currently works at Novartis AG, a leading global healthcare company. His role has enabled him to contribute to novel pharmaceutical advancements and the refinement of drug development processes. Over the years, he has built a reputation as a skilled inventor whose insights have led to enhanced treatment options for complex health conditions.

Collaborations

Throughout his career, Frederiksen has collaborated with talented colleagues such as Dominik Feuerbach and Bernard Lucien Roy. These partnerships have fostered a rich environment for innovation, allowing for the integration of diverse expertise and the realization of groundbreaking projects.

Conclusion

Mathias Frederiksen stands out as an influential inventor in the realm of pharmaceutical science. His extensive patent portfolio reflects not only his commitment to addressing critical health challenges but also his ability to transform innovative ideas into practical applications. With ongoing collaborations and a forward-thinking approach, Frederiksen’s contributions will undoubtedly continue to shape the future of medical research and treatment.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…